This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Antengene Corp. (cancer and infectious disease drug development) raised $120mm through its Series B round. Boyu Capital and FountainVest led and were joined by Celgene, Wuxi Corporate Venture Fund, and Taikang, along with returning backers Qiming Venture Partners and TF Capital. Proceeds will support continued development of lead projects ATG008, a second generation TORC1/2 inhibitor in-licensed from Celgene and in Phase II for HBV+ hepatocellular carcinoma, and ATG010 (selinexor), in Phase III for blood and solid tumors including multiple myeloma, diffuse large B-cell lymphoma, liposarcoma, and glioblastoma. The company previously raised $21mm in its 2017 Series A round.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?